Wednesday, 18 Oct 2017

You are here

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com. 

  1. Amgen submitted its Biologic Licence application to the FDA for Denosumab in Rx of Glucorticoid induced Osteoporosis https://t.co/MdKOssFggV
  2. 165 scleroderma pts double pos for centromere & anti–IFI-16 Abs incr. risk for digital vascular events, >3 fold higher odds of Severe Raynauds https://t.co/ueOuUC7R2O  
  3. IBD clinic study shows CT-Dx sacroiliitis found in 15% of 233 Crohns, 16.9%, of 83 UC pts & 5.6% 108 controls https://t.co/O2WuJoUPL6
  4. Among 608 SSc pts 3% developed Scl renal crisis - risk w/ digital gangrene, pred >15, alb <3, cardiac involvement https://t.co/R6HpDSbk3R
  5. Hospitalizationsfor Serious infections increased from 90 to 206  per 100,000 PY from 1993-2013. Sepsis tripled. But pneumonia, UTI & OIs decreased https://t.co/rHL5pJHMSc
  6. No Increase in Malformations with Etanercept Use During Pregnancy
  7. Lupus Hospitalizations are Common 
  8. Arthritis Advisory Panel Votes Down Sirukumab  
  9. FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.